Published in Vaccine Weekly, June 16th, 2004
The phase II study is designed to determine the safety and efficacy of a novel therapeutic concept under development by NovaRx. In contrast to conventional cancer therapies, where chemotherapeutic drugs destroy the tumor, the therapeutic vaccine developed by NovaRx enhances the patient's own immune system in order to fight the cancer. In clinical studies to date, the side effects of this treatment have been shown to be far less than those associated with traditional...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly